Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Century Vision Global (CVG) is a private ophthalmology-focused company creation platform and holding company based in New York. Founded by industry pioneers Dr. David Guyer and Dr. Jason Slakter, the firm specializes in identifying and developing innovative therapies for retinal diseases. CVG's most significant achievement is the incubation of EyeBiotech (EyeBio), which developed the novel Wnt signaling agonist Restoret. In 2024, EyeBio was acquired by Merck for up to $3 billion, validating CVG's model of rapid, expert-led drug development. CVG continues to leverage its deep clinical and scientific network to advance next-generation treatments for vision loss.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Century Vision Global.